MTOR and nonpapillary renal cell carcinoma: Preclinical data suggest that METTL3 inhibition synergizes with mTOR inhibitors (e.g., everolimus) by disrupting hypoxia-inducible factor-2α (HIF-2α)-driven metabolic adaptation, a hallmark of ccRCC (Zhan et al., 2023) (Table 2).